Platinum drugs upregulate CXCR4 and PD‐L1 expression via ROS‐dependent pathways, with implications for novel combined treatment in gastric cancer
Open Access
- 27 January 2025
- journal article
- research article
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 11 (1) , e70015
Abstract
CXC chemokine receptor 4 (CXCR4) and programmed cell death‐ligand 1 (PD‐L1) are two critical molecules involved in the tumor immune microenvironment. However, the impact of platinum drugs, such as cisplatin, on CXCR4 or PD‐L1 expression and the underlying mechanisms in gastric cancer (GC) remain unknown. Moreover, the correlation between their expression levels in GC remains elusive. Immunohistochemistry, western blot, and RT‐qPCR were performed to determine the expression pattern of CXCR4 and PD‐L1 in GC. Clinical samples, patient‐derived xenografts, and cell‐derived xenografts were utilized to investigate the effects of platinum drugs on the expression levels of CXCR4 and PD‐L1. Postchemotherapy resected GC tumor tissues showed higher CXCR4 and PD‐L1 expression levels than pretreatment biopsies (p < 0.05). Similarly, GC xenografts treated with platinum‐based chemotherapy exhibited increased CXCR4 and PD‐L1 expression levels compared to saline‐treated controls (p < 0.05). A positive correlation was detected between the expression levels of CXCR4 and PD‐L1 in GC tumor tissues. Increased levels of CXCR4 and PD‐L1 expression, in a dose‐ and time‐dependent manner upon cisplatin treatment, were observed in GC cells (p < 0.05). Cisplatin‐induced CXCR4 upregulation relies on ROS/HIF‐1α and ROS/NF‐κB pathways, while cisplatin‐induced PD‐L1 upregulation is cyclic GMP‐AMP synthase/stimulator of IFN genes‐dependent and associated with elevated ROS levels in GC cells. CXCR4 expression was found to be positively correlated with PD‐L1 expression in GC. Platinum drugs upregulated the levels of CXCR4 and PD‐L1 expression in GC. A combined strategy targeting CXCR‐4 and PD‐L1 might have clinical prospects for GC patients.Keywords
Funding Information
- Fundamental Research Funds for the Central Universities (2021RC258)
- National Natural Science Foundation of China (81903075, 82003152, 82103524, 82373117)
- China Postdoctoral Science Foundation (2021M700366)
This publication has 46 references indexed in Scilit:
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialThe Lancet Oncology, 2014
- Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With TrastuzumabJournal of Clinical Oncology, 2013
- Residual Prostate Cancer Cells after Docetaxel Therapy Increase the Tumorigenic Potential via Constitutive Signaling of CXCR4, ERK1/2 and c-MycMolecular Cancer Research, 2013
- An Undesired Effect of ChemotherapyJournal of Biological Chemistry, 2013
- CXCR4/CXCL12 Mediate Autocrine Cell- Cycle Progression in NF1-Associated Malignant Peripheral Nerve Sheath TumorsCell, 2013
- HER2 Interacts With CD44 to Up-regulate CXCR4 via Epigenetic Silencing of microRNA-139 in Gastric Cancer CellsGastroenterology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Autocrine Induction of Invasive and Metastatic Phenotypes by the MIF-CXCR4 Axis in Drug-Resistant Human Colon Cancer CellsCancer Research, 2010
- Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cellsCell Research, 2008
- Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cellsBritish Journal of Cancer, 1997